Giuseppe Curigliano: ESMO Recommendations on Molecular Tumour Boards in Clinical Practice
Giuseppe Curigliano, Member of the Editorial Board for OncoDaily and President Elect of ESMO, posted on LinkedIn, about recent paper he and colleagues co-authored:
“Just published in Annals of Oncology: “ESMO Precision Oncology Working Group Recommendations on the Structure and Quality Indicators for Molecular Tumour Boards in Clinical Practice”.
This paper marks a significant step forward in ESMO’s commitment to expanding access to precision oncology across Europe and beyond.
- Why it matters: Molecular Tumour Boards (MTBs) are critical to interpreting complex genomic data and guiding personalized treatment decisions. But without clear structure and quality standards, their potential is underused and unevenly distributed.
- What’s new: ESMO proposes a comprehensive framework for the optimal setup, functioning, and evaluation of MTBs—aimed at ensuring high-quality, equitable molecular diagnostics and therapy matching for all cancer patients, not just a privileged few.
- The goal: democratize access to precision medicine by promoting standardized, multidisciplinary, and inclusive MTB models.
ESMO continues to lead the way in making precision oncology a reality for every patient, everywhere.”
Authors: C.B. Westphalen, L. Boscolo Bielo, P. Aftimos, H. Beltran, M. Benary, D. Chakravarty, M. Collienne, R. Dienstmann, A. El Helali, J. Gainor, P. Horak, C. Le Tourneau, C. Marchiò, C. Massard, F. Meric-Bernstam, C. Pauli, G. Pruneri, F. Roitberg, H.E.G. Russnes, D.B. Solit, G. Curigliano
Read Further: Oncologist Near Me – Giuseppe Curigliano: A Prominent Specialist in Breast Cancer Clinical Trials and Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023